Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

An artificial intelligence (AI)-based technology rapidly diagnoses rare disorders in critically ill children with high accuracy, according to a report by researchers from University of Utah (U Of U) Health, Fabric Genomics, and collaborators on a study led by Rady Children’s Hospital in San Diego.

DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.

On November 10, Wuhan Landing Med officially announced that it had completed the round-D financing of RMB 320 million, which was led by Ali Health and followed by Ether Capital.

The funding will be used to provide purchase commitments to manufacturers so they can scale up test production.

Meridian Bioscience announced on Wednesday that its Revogene SARS-CoV-2 test has received Emergency Use Authorization from the US Food and Drug Administration.

Britain said it would recognise COVID-19 vaccines on the World Health Organization's Emergency Use Listing later this month.

Viome Life Sciences said Wednesday that it has raised $54M in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over $125M in total.

Point-of-care diagnostics firm LumiraDx on Wednesday reported a sharp year-over-year increase in revenues for the third quarter on sales of test strips for its COVID Ag SARS-CoV-2 antigen test.

GE announced today what Chairman and CEO Larry Culp called a “defining moment,” with plans to form three industry-leading, global public companies focused on the growth sectors of aviation, healthcare and energy.

Castle Biosciences reported after the close of the market on Monday that its third quarter revenues rose 54 percent year over year, thanks to a 62 percent increase in the number of tests delivered during the quarter.